GraniteShares 2x Long COIN Daily ETF vs Moderna, Inc. — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.14, while Moderna, Inc. trades at $67.3 (market cap $26.76B). The key difference: Moderna, Inc. is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| CONL | MRNA | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.57 | $81.80 |
52-Week Low | $4.09 | $22.36 |
Market Cap | — | $26.76B |
Enterprise Value | — | $22.85B |
Signals from Pluang's Aura AI — not financial advice
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.85, down 2.02% on the day, reflecting a challenging year-to-date performance. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure, while oscillators remain neutral. Recent news highlights the fund's volatility, with significant losses tied to Coinbase stock swings and leveraged daily resets.
The outlook remains highly speculative, offering potential for explosive gains if Bitcoin rallies but carrying substantial risk from daily leverage decay and Coinbase volatility. Investors face amplified losses in downturns, making this suitable only for short-term traders with high risk tolerance.
Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.
While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.
Trailing returns across standard periods
Latest headlines on both assets
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →